Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

wintogether May. 22 at 5:26 PM

$BNTX the volume right now is about as much as the volume afterhours yesterday. Trapped traders are selling for a loss, it seems. Just an observation. No hypothesis. Real move happens when the full data comes out on June 1.

0 · Reply

eightytwentie May. 22 at 3:37 PM

$BNTX the market is inefficient in digesting this info Even Moderna’s info was encouraging

0 · Reply

htw7448 May. 22 at 2:13 PM

$BNTX i would be surprised if we close below 94$

0 · Reply

TheRealShortSqueezy May. 22 at 2:10 PM

🚨 $CUE Entering a New Growth Phase With Major 2026 Catalysts Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer. Cue Biopharma continues stacking catalysts in 2026: 🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors. 🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets. 🔹 Company also secured a $30M private placement to strengthen the balance sheet and support pipeline expansion. 🔹 Received a $7.5M milestone payment from Boehringer Ingelheim. With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech. Communicated Disclaimer: https://stockresearchtoday.com/cue/ Sector peers: $MRNA $BNTX $NKTX $IMTX

0 · Reply

birdflustocks May. 22 at 12:42 PM

$ARCT Arcturus Therapeutics: Strategic opportunities beyond CSL A comprehensive analysis about a potential pivot to new collaboration partners in the mRNA space, covering $ARCT ASX:CSL $BNTX $SNY $MRNA and more. 0% AI, 100% free https://birdflustocks.substack.com/p/arcturus-therapeutics-strategic-opportunities

0 · Reply

AIIAAIIA_88 May. 22 at 12:07 PM

$BNTX Judging from the OI of put options (11,000 at $80 strike), there are many skeptics of BNTX being able to succeed with its cancer pipeline. Oh, ho… the bears and short sellers will have a horrid year… lol. I am just saying..

1 · Reply

htw7448 May. 22 at 10:10 AM

$BNTX heavy premarket volume

0 · Reply

htw7448 May. 22 at 9:37 AM

$BNTX image Keytruda losing his SOC to Pumitamig. 25 Billion$ per year! If this happen and data already hinting it … impressive growth ahead! The actual Market cap is a joke nothing of the news is priced in!

0 · Reply

birdflustocks May. 22 at 7:34 AM

https://birdflustocks.substack.com/p/arcturus-therapeutics-strategic-opportunities Arcturus Therapeutics: Strategic opportunities beyond CSL A comprehensive analysis about a potential pivot to new collaboration partners, covering $ARCT ASX:CSL $BNTX $SNY $MRNA and more. 0% AI, 100% free

0 · Reply

eightytwentie May. 22 at 12:24 AM

$BNTX https://www.asco.org/abstracts-presentations/261380

0 · Reply

Market Cap	23.30B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	668,700
Avg Vol	935,544
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	66%
Beta	1.36
Analysts	Strong Sell
Price Target	$129.60